Gazelle Book Services Limited.
White Cross Mills, Hightown, LANCASTER LA1 4XS, United Kingdom.
Telephone: +44(0)1524 68765
Fax: +44(0)1524 63232
Email: sales@gazellebooks.co.uk
Web: www.gazellebooks.co.uk
| Title: | Testicular Cancer Research Trends
|
| Author: | Paulo V Brantus (ed) |
| ISBN: | 1600216676 : 9781600216671 |
| Illustrations: | b/w tables & illus |
| Format: | Hardback |
| Size: | 180x260mm |
| Pages: | 144 |
| Weight: | .552 Kg. |
| Published: | Nova Science Publishers - February 2007 |
| List Price: | 107.5 Pounds Sterling |
| Availability: | In Print |
| Subjects: | Oncology |
Seminomas account for about 30-40% of all testicular tumours. These are usually is found in men in their 30s and 40s. The condition is usually localised to the testes, although in about 25% of cases it has spread to lymph nodes. Non-seminomas account for 60% of all testicular tumours; subcategories of these tumours are listed below. Non-seminoma tumours often contain more than one of the following cell types: Testicular cancer is an abnormal, rapid, and invasive growth of cancerous (malignant) cells in the testicles. Embryonal carcinoma (about 20% of testicular cancers) occurs in 20-30 year olds and is highly malignant. It grows rapidly and spreads to the lung and liver. Yolk sac tumour (about 60% of all testicular cancers in young boys). Teratomata (about 7% of testicular cancers in adult men and 40% in young boys). Choriocarcinoma is rare. Stromal cell tumours are a kind of tumour that is made of Leydig cells (testosterone-secreting cells), Sertoli cells (cells where sperm matures), and granulose cells. These tumours account for only 3-4% of all testicular tumours. However, they do make up nearly 20% of all childhood testicular tumours. These tumours may secrete a hormone -- estradiol -- that can cause one of the symptoms of testicular cancer, gynecomastia (excessive development of breast tissue). This book presents leading-edge research in the field.
Preface; Metastatic Risk Assessment in Nonseminomatous Germ Cell Testicular Cancer; Expression of Bcl-2 Family Members in Testicular Germ Cell Tumours; Treatment of Germ Cell Tumours relapsed after Cisplatin-based Chemotherapy; Correlation between Spanx Gene Expression and Testicular Germ Cell Tumours; Novel Therapeutic Strategies for the Treatment of Testicular Germ Cell Tumours; Long-term Experiences with Differentiated Therapeutic Approach in Patients with Clinical Stage I Nonseminomatous Germ Cell Testicular Tumours- Comparison with Orchiectomy Alone and Surveillance Regimen; What have we learned after ten years of Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer?; The Management of Clinical Stage I Non-Seminoma Germ Cell Cancer; Index.
